№ files_lp_4_process_1_42314
File format: docx
Character count: 5940
File size: 27 KB
Year:
2021
Study type:
Clinical research
Document type:
Supplementary materials
Authors:
Not specified
Institution:
Not specified
Target audience:
Researchers in oncology and virology
Tumor types:
Glioma, Meningioma, Pituitary adenoma, Craniopharyngioma, Ependymoma, Schwannoma, Haemangioblastoma, Chordoma, Brain metastases from breast, lung, kidney, colon cancer
Methods:
Immunohistochemistry, Immunofluorescence, Gene expression analysis, KEGG enrichment, GSEA
Patient information:
Age, Sex, Preexisting conditions, Preoperative treatment, SARS-CoV-2 PCR status
Figures included:
S1–S6
Tables included:
S1
Key markers analyzed:
ACE2, TMPRSS2, CD147, NRP1, IFN-γ, PD-1, FOXP3, CD8, CD4, C1q, C3, IgG, IgM, CD68, TTF1, MUC1
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.
The file will be delivered to the email address provided at checkout within 12 hours.
Don’t have cryptocurrency yet?
You can still complete your purchase in a few minutes:- Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
- In the app, tap Send.
- Select network, paste our wallet address.
- Send the exact amount shown above.
The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Note:
Year
Region / City:
Shanghai, China
Topic:
Tumor Immunology, Hepatocarcinogenesis
Document Type:
Research Supplementary Material
Institution:
Third Affiliated Hospital of Second Military Medical University, National Center for Liver Cancer
Author:
Chen Zong, Yan Meng, Fei Ye, Xue Yang, Rong Li, Jinghua Jiang, Qiudong Zhao, Lu Gao, Zhipeng Han, Lixin Wei
Target Audience:
Researchers in Tumor Immunology, Oncology
Context:
A research document providing detailed methods and experimental procedures on hepatocarcinogenesis and tumor immunology based on single-cell analysis and cell culture experiments.
Year:
2023
Region / city:
Zabol, Iran
Theme:
Cancer research, Oncology
Document Type:
Review Article
Organization:
Asian Oncology Research Journal
Author:
Ferydoon Khamooshi
Target Audience:
Scientific community
Period of validity:
Not specified
Approval Date:
Not specified
Date of changes:
Not specified
Year:
2020
Region / city:
Global
Theme:
COVID-19 Pandemic, Health Risk Assessment
Document type:
Report
Organization:
Centers for Disease Control and Prevention (CDC), World Health Organization (WHO)
Author:
Centers for Disease Control and Prevention (CDC)
Target audience:
Public health officials, healthcare providers, researchers
Validity period:
Ongoing
Approval date:
October 19, 2020
Date of changes:
Ongoing
Year:
2020
Region / City:
New South Wales, Australia
Topic:
Biology, SARS-CoV-2, RNA, Vaccination, Infectious Diseases
Document Type:
Educational Resource
Organization / Institution:
New South Wales Education Standards Authority (NESA)
Author:
Not specified
Target Audience:
Year 12 students
Period of Validity:
2020 and onwards
Approval Date:
2017
Date of Changes:
Not specified
Year:
2021
Region / city:
United States
Topic:
COVID-19, occupational health, risk assessment
Document type:
Report
Organization / institution:
CSTE Occupational Health Subcommittee
Author:
CSTE Occupational Health Subcommittee, Work Group on Essential Workers - Exposure Measures Team
Target audience:
Epidemiologists, policymakers, occupational health experts
Effective period:
From August 18, 2021
Approval date:
August 18, 2021
Date of changes:
August 18, 2021
Year:
2020
Region:
Guangdong Province, China
Topic:
Genomic epidemiology of SARS-CoV-2
Document type:
Supplementary information to a scientific research article
Associated article:
Genomic epidemiology of SARS-CoV-2 in Guangdong Province, China
Authors:
Jing Lu; Louis du Plessis; Zhe Liu; Verity Hill; Min Kang; Huifang Lin; Jiufeng Sun; Sarah François; Moritz U G Kraemer; Nuno R Faria; John T McCrone; Jingju Peng; Qianlin Xiong; Runyu Yuan; Lilian Zeng; Pingping Zhou; Chuming Liang; Lina Yi; Jun Liu; Jianpeng Xiao; Jianxiong Hu; Tao Liu; Wenjun Ma; Wei Li; Juan Su; Huanying Zheng; Bo Peng; Shisong Fang; Wenzhe Su; Kuibiao Li; Ruilin Sun; Ru Bai; Xi Tang; Minfeng Liang; Josh Quick; Tie Song; Andrew Rambaut; Nick Loman; Jayna Raghwani; Oliver G Pybus; Changwen Ke
Affiliated institutions:
Guangdong Provincial Center for Disease Control and Prevention; University of Oxford; University of Edinburgh; Shenzhen Center for Disease Control and Prevention; Guangzhou Center for Disease Control and Prevention; Guangdong Provincial Second People’s Hospital; Foshan First People’s Hospital; University of Birmingham
Data coverage period:
Up to 19 March 2020
Number of reported genomes:
53 newly reported SARS-CoV-2 genomes
Total cases referenced:
1388 laboratory-confirmed COVID-19 cases
Figures:
S1–S4
Tables:
S1–S2
Data sources:
RT-PCR testing; whole-genome sequencing; GISAID database
Geographic scope of comparative data:
Guangdong; Hubei; USA (California, Wisconsin); Japan; Singapore; Jiangsu; Fujian; India; Vietnam
Year:
2021
Region / city:
Various locations in the United States
Topic:
COVID-19 Treatment
Document type:
Clinical Trial Report
Institution:
Regeneron Pharmaceuticals, NIAID/CoVPN
Author:
Multiple investigators and research teams
Target audience:
Healthcare professionals, researchers, clinical trial coordinators
Period of validity:
Study conducted during 2020-2021
Approval date:
Not specified
Date of changes:
Not specified
Document Type:
Supplementary data appendix
Subject:
Development and validation of a rapid viability RT-PCR (RV-RT-PCR) method for detection of infectious SARS-CoV-2
Pathogen:
SARS-CoV-2
Experimental Model:
Vero E6 cells
Institutions:
U.S. Environmental Protection Agency, Office of Research and Development; Lawrence Livermore National Laboratory
Authors:
Sanjiv R. Shah; Staci R. Kane; Maher Elsheikh; Teneile M. Alfaro
Geographic Location:
Washington, District of Columbia, USA; Livermore, California, USA
Data Type:
RT-PCR cycle threshold (CT) measurements; plaque forming units (PFU); TCID50 values; recovery efficiency data
Infection Conditions:
1-hour and 2-hour infection periods with post-infection incubation at T0, T12, and T24
Sample Type:
SARS-CoV-2-infected cell cultures and swab swatches
Analytical Replicates:
Triplicate RT-PCR analyses with pooled standard deviations
Tables Included:
Table S1; Table S2; Table S3; Table S4
Year:
2022
Region / City:
N/A
Subject:
Molecular interaction studies
Document Type:
Supplementary data
Organization / Institution:
N/A
Author:
N/A
Target Audience:
Researchers in biochemistry, molecular biology, and virology
Period of Validity:
N/A
Approval Date:
N/A
Modification Date:
N/A
Year:
2026
Region / Institution:
Not specified
Topic:
Immunology, SARS-CoV-2, Vaccine Response
Document type:
Peer Review
Author:
Stefania P Bjarnarson
Target audience:
Researchers, Immunologists
Study period:
Up to 33 months post mRNA vaccination
Methods:
Analysis of bone marrow plasma cells, healthy adult donors, post-vaccination sampling
Key findings:
Limited presence of SARS-CoV-2-specific long-lived plasma cells in bone marrow after mRNA vaccination or hybrid immunity
Data source:
Bone marrow aspirates, hip joint replacement surgery samples
Limitations:
Small sample size, discrepancies in patient description, consideration of asymptomatic infections
Scientific relevance:
Provides evidence on the longevity of humoral immune response post-vaccination
Concise description:
Peer-reviewed evaluation of a study assessing the presence of SARS-CoV-2-specific long-lived plasma cells in the bone marrow following mRNA vaccination and hybrid immunity, highlighting methodology, key results, and points for revision.
Year:
2020
Region / city:
United States, multiple states
Theme:
SARS-CoV-2, Healthcare personnel, COVID-19
Document type:
Protocol
Organization / institution:
Centers for Disease Control and Prevention (CDC), Emerging Infections Program
Author:
CDC Division of Healthcare Quality Promotion
Target audience:
Healthcare personnel, public health professionals, researchers
Period of action:
2020
Date of approval:
July 17, 2020
Date of changes:
Not specified
Context description:
Protocol for tracking SARS-CoV-2 infections and assessing risks among healthcare personnel in the United States during the COVID-19 pandemic.
Year:
2020
Region / city:
United States
Topic:
Healthcare personnel, SARS-CoV-2, COVID-19
Document Type:
Protocol
Organization:
Centers for Disease Control and Prevention (CDC), Emerging Infections Program
Author:
Centers for Disease Control and Prevention (CDC)
Target Audience:
Healthcare personnel, public health officials, researchers
Period of Validity:
Ongoing
Approval Date:
April 22, 2020
Date of Changes:
Not specified
Note:
Year
Organization / Institution:
Department of Housing and Public Works
Context:
Form used by external organizations to request installations or alterations to properties leased from the Department of Housing and Public Works.
Year:
2021
Region / City:
Welwyn Garden City
Subject:
Planning application for residential extensions
Document Type:
Planning application
Authority / Institution:
Welwyn Hatfield Borough Council
Author:
Mr James Homer
Target Audience:
Residents of Welwyn Garden City, property developers, architects
Period of Action:
Until 4 May 2024
Approval Date:
05 May 2021
Modification Date:
None
Bid Number:
ECR/SCM/PRCL2/EL/10/2021
Closing Date:
21 January 2022
Closing Time:
12:00 NOON
Delivery Address:
Passenger Rail Agency of South Africa, PRASA CRES, 8 Station Street Station Building, East London
Location:
East London, South Africa
Scope:
Refurbishment, alterations, and additions at Mtsotso, Mdantsane, Mount Ruth, and Egerton Station
Duration:
12 months construction period
Type:
Request for Proposal (RFP)
Issuing Organization:
Passenger Rail Agency of South Africa (PRASA)
Confidentiality Requirements:
Applicable to all bidders and associated parties
Regulatory Notice:
Recipients outside South Africa should observe relevant local regulations
Document code:
OG518
Document type:
Regulatory guidance
Subject:
Amendments to governing documents of charitable companies
Legal basis:
Charities Act 2011, section 198
Jurisdiction:
England and Wales
Regulatory authority:
Charity Commission
Target audience:
Charity Commission caseworkers
Applies to:
Charitable companies limited by guarantee
Exclusions:
Charter companies, charitable incorporated organisations, other incorporated charities
Last reviewed:
16 April 2013
Last updated:
25 April 2019
Covers regulated alterations:
Yes
Includes case studies:
Yes
Includes legal and policy framework:
Yes
Year:
2018
Region / City:
Australia
Theme:
Building regulations, construction design
Document Type:
Performance-based design brief
Organ / Institution:
National Construction Code
Author:
Not specified
Target Audience:
Building professionals, surveyors, architects
Validity Period:
Not specified
Approval Date:
Not specified
Amendment Date:
2019
Year:
2014
Region / City:
Oregon
Topic:
Accessibility, Building Code Compliance
Document Type:
Statewide Code Interpretation
Organization:
Building Codes Division, Department of Consumer and Business Services, State of Oregon
Author:
Not specified
Target Audience:
Builders, Architects, Contractors, Regulatory Authorities
Effective Period:
Not specified
Approval Date:
Nov. 3, 2014
Last Updated:
Oct. 1, 2019
Year:
2023
Region / City:
Hyderabad, Telangana, India
Subject:
Metabolomics, Plasma Profiling, Pre-Diabetes, Non-Diabetic CP Patients
Document Type:
Supplementary Information
Organization / Institution:
Translational Research Centre, Asian Healthcare Foundation, AIG Hospitals, CSIR-Indian Institute of Chemical Technology
Authors:
Ketavarapu Vijayasarathy, Addipilli Ramunaidu, Nagarjunachary Ragi, Pallerla Pavankumar, Venu Simhadri, Suvidha Manne, Sannapaneni Krishnaiah, Mohsin Aslam, Rupjyoti Talukadar, Ch. Venkataramana Devi, G.V. Rao, Ramars Amanchy, D. Nageshwar Reddy, Prabhakar Sripadi, Mitnala Sasikala
Target Audience:
Researchers, Healthcare professionals in metabolomics and diabetes research
Period of Validity:
Not specified
Approval Date:
Not specified
Date of Changes:
Not specified